– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease –
– ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects…Read More
You might also be interested in reading Hyperliquid Hits New Highs, Solana Surges, BlockDAG Steals the Spotlight With $2M Raised in 24 Hours.